Nasser Aghdami
After a year of challenge with Covid-19, we have now gained extensive experiences in the treatment of this pandemic infection. At the same time, we have learned that the complexity of the diseases requires additional and novel treatment strategies. Among these strategies cell therapy is of high interest.It seems exacerbated immune responses play critical roles in the severity of covid-19 patients and systemic manifestations of are associated with cytokine release storm due to immune system hyperactivity. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function by paracrine secretion or make direct interactions with immune cells.To date, one randomized double blind clinical trial has been reported that UC-MSC infusions in COVID-19 subjects with ARDS were safe and associated with reduction in mortality and time to recovery.Apart from the mentioned trial there are several non-randomized and case series trials that employed MSC for treatment of COVID-19 patient including our study in Royan Institute. More than sixty study registered in NIH that requiting COVID patients for MSC therapy.Although there is promising data regarding of MSC therapy however data for critical and sever patients are controversy and in this presentation, I am going to have a look for recent studies in this field and challenges of MSC therapy in COVID patients.